Royal Bank Of Canada began coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a report issued on Thursday morning. The brokerage issued a sector perform rating and a $120.00 target price on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. Cowen and Company set a $145.00 price objective on shares of TESARO and gave the company a hold rating in a report on Saturday, June 10th. Janney Montgomery Scott set a $139.00 price objective on shares of TESARO and gave the company a hold rating in a report on Saturday, June 10th. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a buy rating in a report on Friday, August 18th. FBR & Co lowered their target price on shares of TESARO from $200.00 to $195.00 and set a mkt perform rating on the stock in a report on Monday, June 5th. Finally, Robert W. Baird restated a neutral rating on shares of TESARO in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. TESARO presently has an average rating of Buy and a consensus target price of $171.42.
Shares of TESARO (NASDAQ:TSRO) opened at 117.16 on Thursday. The firm has a 50 day moving average price of $121.74 and a 200 day moving average price of $140.42. The firm’s market cap is $6.35 billion. TESARO has a 1-year low of $96.52 and a 1-year high of $192.94.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the company posted ($1.28) EPS. TESARO’s revenue for the quarter was down 17.6% on a year-over-year basis. Analysts anticipate that TESARO will post ($8.67) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Coverage Initiated at Royal Bank Of Canada” was first reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/tesaro-inc-tsro-coverage-initiated-at-royal-bank-of-canada/1645288.html.
In related news, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. Insiders have sold a total of 25,100 shares of company stock valued at $3,387,465 over the last three months. Insiders own 34.60% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSRO. Botty Investors LLC bought a new position in TESARO in the 2nd quarter worth approximately $140,000. Nordea Investment Management AB bought a new position in TESARO in the 2nd quarter worth approximately $167,000. Meeder Asset Management Inc. bought a new position in TESARO in the 1st quarter worth approximately $177,000. Oppenheimer Asset Management Inc. boosted its holdings in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the period. Finally, BB&T Securities LLC bought a new position in TESARO in the 2nd quarter worth approximately $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.